Uptake of Merck KGaA’s Mavenclad in the European Multiple Sclerosis Market Currently Stalled Due to Restrictive Guidelines and Pending Additional Country-Level Approvals
Early launch of Roche’s Ocrevus has surpassed Mavenclad due to first-in-market primary progressive multiple sclerosis label and broad access through compassionate use programs, although transitioning to country-level health plans may slow future momentum, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., March 27, 2018 /PRNewswire/ — With an additional […]
Gastroenterologists Are Gearing Up to Incorporate Novel Oral Agents, Such As Pfizer’s Xeljanz, into the Treatment Paradigm for Ulcerative Colitis, According to Latest Data from Spherix Global Insights
Surveyed gastroenterologists (n=101) estimate that 80% of their patients with ulcerative colitis (UC) who were started on a biologic in the past year would have preferred to start with an oral instead, highlighting the massive opportunity not just for Xeljanz, but also for other JAK inhibitors and small molecule agents in the pipeline Download Report […]
Genentech’s Ocrevus Begins to Move the Needle on the Treatment Rate for Primary Progressive Multiple Sclerosis but May Not Be the Only Disease-Modifying Therapy in Play
Irrespective of Celgene’s recent receipt of a refusal-to-file letter for ozanimod, neurologists are eagerly awaiting a secondary progressive multiple sclerosis indication for Novartis’ siponimod, but are more divided on the value EMD Serono’s Mavenclad will bring to their practices, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., March 13, […]
Next Generation Biologics, Janssen’s Tremfya, Eli Lilly’s Taltz, and Novartis’ Cosentyx, Raising the Bar in Psoriasis Management
A recent study published by Spherix Global Insights reveals that the newest psoriasis entrant, Tremfya, has made substantial gains in penetrating first-line biologic therapy for psoriasis. Download Report Overview EXTON, Pa., March 8, 2018 /PRNewswire/ — The past three years have brought with them a flurry of branded biologic approvals in dermatology, including four biologics […]
As Lilly Deals with Yet Another Set-Back in Entering the US Rheumatoid Arthritis Market, Pfizer’s Xeljanz Further Solidifies Its Position as a Go-To Alternate Mechanism of Action Agent, According to a Recently Published Study by Spherix Global Insights
Though baricitinib (Olumiant) has been resubmitted for FDA approval, time lost on the US market has opened up doors for Xeljanz Download Report Overview EXTON, Pa., Feb. 20, 2018 /PRNewswire/ — Since receiving a Complete Response Letter from the FDA for their Incyte partnered investigational JAK 1/2 inhibitor, baricitinib (Olumiant), Eli Lilly’s entrance into the […]
Spherix Global Insights Announces Collaboration with Oncology Industry Experts to Expand Portfolio of Independent Reports Covering Highly Dynamic Markets
The initial coverage focuses on an in-depth quarterly analysis of the evolving multiple myeloma market Download Report Overview EXTON, Pa., February 13, 2018 /PRNewswire/ – Spherix Global Insights is a recognized market intelligence agency providing independent coverage of the autoimmune, multiple sclerosis, and nephrology markets. Unlike other firms offering syndicated reports, Spherix derives actionable insights […]
Growth of Sanofi-Regeneron’s Dupixent in Atopic Dermatitis May Be Facing Its First Plateau, while Pfizer’s Eucrisa Carves a Niche with Younger Patients
While dermatologists satisfaction with Dupixent is exceptionally high and nearly all consider it an advance over other treatment options, Q1 2018 marks the first quarter with no significant gains in the user base or average number of patients being treated, according to the latest quarterly update from Spherix Global Insights Download Report Overview EXTON, Pa., […]
Amgen’s Parsabiv Starts to Gain Ground in US Dialysis Market with the Nephrology User Base Expected to Climb from 20% to Over 80% Within the Next Six Months
In addition to converting patients from Amgen’s own oral calcimimetic, Sensipar, nephrologists anticipate an increase in the calcimimetic class overall as a result of Parsabiv’s introduction, according to a survey conducted by Spherix Global Insights last week. Download Report Overview EXTON, Pa., Feb. 1, 2018 /PRNewswire/ — It has been nearly a year since Amgen […]
Ustekinumab Makes Inroads in Crohn’s Disease – Docs opt for psoriasis drug when anti-TNF agents fail
From: MedPage Today Byy: Ed Susman, Contribution Writer, MedPAge Today LAS VEGAS — TNF inhibitors remain the predominant treatment in Crohn’s disease, but ustekinumab (Stelara) has been quickly adopted by clinicians, accounting for about one in five recently switched patients, researchers reported here. The agent received FDA approval in 2016 for the treatment of moderately […]
Heavy-hitting MS Therapies Now Being Used Sooner for Some Patients
From: Multiple Sclerosis News Today By: Ed Tobias However, a recent audit of patients and neurologists by Spherix Global Insights, a business intelligence and market research company, reports an apparent change in attitude about cost…(read more).
